Sugi Predict

Sugi Predict / Compounds / SCHEMBL1594449

SCHEMBL1594449

SCHEMBL1594449

Cc1cc(Cl)ccc1NC(=O)Nc1cn(CC2CC2)c(C(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MDM2 Q00987 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HTT P42858 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ MAPT P10636 5/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ F11 P03951 1/20 0.38
▸ KLK1 P06870 1/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ IDH1 O75874 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1594765 0.89 TP53 (0.40) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL27688542 0.86 F11 (0.35) MDM2MAPTLMNAPOLBF11
SCHEMBL2570520 0.85 MEN1 (0.39) MEN1KMT2AMDM2ALDH1A1HTT
SCHEMBL12706245 0.84 LMNA (0.39) MEN1KMT2AALDH1A1HTTNPSR1
SCHEMBL13197780 0.84 CHRM1 (0.36) MEN1KMT2AALDH1A1HTTMAPT
SCHEMBL1595904 0.84 MAPT (0.42) MEN1KMT2AALDH1A1MAPTLMNA
SCHEMBL2572024 0.84 P2RX7 (0.48) KMT2AMAPTLMNAPOLBRAB9A
SCHEMBL2572465 0.82 MAPK1 (0.39) MEN1KMT2AALDH1A1MAPTATM
SCHEMBL2570872 0.82 MAPK1 (0.39) MEN1KMT2AALDH1A1MAPTATM
SCHEMBL2569122 0.82 MAPT (0.40) MEN1KMT2AALDH1A1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101128455-B Heterocyclylamide-substituted imidazoles AICURIS GMBH & CO KG 2013-01-16 — — CN disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 — — EP disclosed
EP-1732901-B1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND AICURIS GMBH & CO KG (DE) 2011-11-02 — — EP disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7919489-B2 e.g. 4-({[(4-Chloro-2-methylphenyl)amino]carbonyl}amino)-1-(cyclopropylmethyl)-1H-imidazole-2-carboxylic acid; antiviral agents, especially against cytomegaloviruses and other Herpes viridae; side effect reduction; antibiotic resistance AICURIS GMBH & CO. KG (DE) 2011-04-05 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 — — US disclosed
EP-1853582-B1 HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO KG (DE) 2009-10-21 — — EP disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2008-07-24 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 — — US disclosed
EP-1853582-A2 HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES AiCuris GmbH & Co. KG (DE) 2007-11-14 — — EP disclosed
EP-1732901-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND Bayer HealthCare AG (DE) 2006-12-20 — — EP disclosed
WO-2006089664-A2 HETEROCYCLYLAMIDE-SUBSTITUTED IMIDAZOLES AICURIS GMBH & CO. KG (DE) 2006-08-31 — — WO disclosed
WO-2005092865-A1 ANTIVIRAL 4-AMINOCARBONYLAMINO-SUBSTITUTED IMIDAZOLE COMPOUND BAYER HEALTHCARE AG (DE) 2005-10-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176859-A1 HETEROCYCLYAMIDE-SUBSTITUTED IMIDAZOLES TPMT, TYMP, PAICS MEN1 422/4885KMT2A 1448/4885MDM2 395/4885
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 MEN1 1305/4885KMT2A 1870/4885MDM2 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.